Abstract | BACKGROUND: METHODS: The schedule consisted of a first phase of chemotherapy alone and of a second phase of concurrent chemoradiation. Doses were as follows: docetaxel 35 mg/m(2) and cisplatin 25 mg/m(2) on days 1, 8, 15, 29, 36, 43, 50, and 57 plus 5-FU c.i. (180 mg/m(2) on days 1-21 and 150 mg/m(2) on days 29-63); RT (50 Gy) started at day 29. Surgery was planned 6 to 8 weeks after the completion of chemoradiation. RESULTS: A total of 74 patients were enrolled; pathological complete remission (pCR) was found in 47% (35 of 74) and near pCR (microfoci of tumor cells on the primary tumor without lymph nodal metastases) (pnCR) in 15% of the patients (11 of 74). Grade 3-4 neutropenia, nonhematological toxicity, and toxic deaths occurred in 13.5%, 32.4%, and 4% of the patients, respectively. Median follow-up was 55 months (range, 3-108 months). Median survival of all 74 patients was 55 months, whereas it was not reached in the pCR subset. The 3- and 5-year survival rates were, respectively, 83% and 77% for pCR, 73% and 44% for pnCR, and 21% and 14% for Residual Tumor subsets (P < .001). CONCLUSIONS: This study shows that 1) this intensive weekly schedule produced a high pathological response rate, 2) responders had high and long-term durable survival rates.
|
Authors | Felice Pasini, Giovanni de Manzoni, Andrea Zanoni, Antonio Grandinetti, Carlo Capirci, Michele Pavarana, Anna Tomezzoli, Domenico Rubello, Claudio Cordiano |
Journal | Cancer
(Cancer)
Vol. 119
Issue 5
Pg. 939-45
(Mar 01 2013)
ISSN: 1097-0142 [Electronic] United States |
PMID | 23165781
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Copyright | Copyright © 2012 American Cancer Society. |
Chemical References |
- Taxoids
- Docetaxel
- Cisplatin
- Fluorouracil
|
Topics |
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Cisplatin
(administration & dosage)
- Combined Modality Therapy
- Docetaxel
- Drug Administration Schedule
- Esophageal Neoplasms
(drug therapy, mortality, pathology, radiotherapy)
- Female
- Fluorouracil
(administration & dosage)
- Humans
- Male
- Middle Aged
- Neoadjuvant Therapy
- Taxoids
(administration & dosage)
|